<?xml version='1.0' encoding='utf-8'?>
<document id="23179780"><sentence text="Cyclosporine inhibition of hepatic and intestinal CYP3A4, uptake and efflux transporters: application of PBPK modeling in the assessment of drug-drug interaction potential."><entity charOffset="0-12" id="DDI-PubMed.23179780.s1.e0" text="Cyclosporine" /></sentence><sentence text="To apply physiologically-based pharmacokinetic (PBPK) modeling to investigate the consequences of reduction in activity of hepatic and intestinal uptake and efflux transporters by cyclosporine and its metabolite AM1"><entity charOffset="180-192" id="DDI-PubMed.23179780.s2.e0" text="cyclosporine" /></sentence><sentence text="" /><sentence text="Inhibitory potencies of cyclosporine and AM1 against OATP1B1, OATP1B3 and OATP2B1 were investigated in HEK293 cells +/- pre-incubation"><entity charOffset="24-36" id="DDI-PubMed.23179780.s4.e0" text="cyclosporine" /></sentence><sentence text=" Cyclosporine PBPK model implemented in Matlab was used to assess interaction potential (+/- metabolite) against different processes (uptake, efflux and metabolism) in liver and intestine and to predict quantitatively drug-drug interaction with repaglinide"><entity charOffset="1-13" id="DDI-PubMed.23179780.s5.e0" text="Cyclosporine" /><entity charOffset="245-256" id="DDI-PubMed.23179780.s5.e1" text="repaglinide" /><pair ddi="false" e1="DDI-PubMed.23179780.s5.e0" e2="DDI-PubMed.23179780.s5.e0" /><pair ddi="false" e1="DDI-PubMed.23179780.s5.e0" e2="DDI-PubMed.23179780.s5.e1" /></sentence><sentence text="" /><sentence text="Cyclosporine and AM1 were potent inhibitors of OATP1B1 and OATP1B3, IC(50) ranging from 0"><entity charOffset="0-12" id="DDI-PubMed.23179780.s7.e0" text="Cyclosporine" /></sentence><sentence text="019-0" /><sentence text="093 μM following pre-incubation" /><sentence text=" Cyclosporine PBPK model predicted the highest interaction potential against liver uptake transporters, with a maximal reduction of &gt;70% in OATP1B1 activity; the effect on hepatic efflux and metabolism was minimal"><entity charOffset="1-13" id="DDI-PubMed.23179780.s10.e0" text="Cyclosporine" /></sentence><sentence text=" In contrast, 80-97% of intestinal P-gp and CYP3A4 activity was reduced due to the 50-fold higher cyclosporine enterocytic concentrations relative to unbound hepatic inlet"><entity charOffset="98-110" id="DDI-PubMed.23179780.s11.e0" text="cyclosporine" /></sentence><sentence text=" The inclusion of AM1 resulted in a minor increase in the predicted maximal reduction of OATP1B1/1B3 activity" /><sentence text=" Good predictability of cyclosporine-repaglinide DDI and the impact of dose staggering are illustrated"><entity charOffset="24-36" id="DDI-PubMed.23179780.s13.e0" text="cyclosporine" /></sentence><sentence text="" /><sentence text="This study highlights the application of PBPK modeling for quantitative prediction of transporter-mediated DDIs with concomitant consideration of P450 inhibition" /><sentence text="" /></document>